Alligator Bioscience to address immunogenicity with Epibase®
Lund, Sweden and Ghent, Belgium - October 09, 2006 - Alligator Bioscience AB and AlgoNomics NV today announced that they have entered into a collaboration. AlgoNomics will employ its Epibase® platform to complement Alligator Bioscience in the optimization of therapeutic proteins both in their internal projects and in collaborative projects with customers. The collaboration allows Alligator to maximally reduce immunogenicity upon optimization of protein therapeutics with their proprietary ssDNA recombination technology FIND®.
“All proteins delivered as biopharmaceuticals could render an immune response. For Alligator it is of great importance to make a responsible risk assessment on any new project. We are therefore grateful to be able to work with AlgoNomics, delivering a state of the art technology, for investigating the theoretical consequence of an immune response”, stated Dr. Gun-Britt Fransson, CEO of Alligator Bioscience.
Dr. Ignace Lasters, CEO of AlgoNomics, comments: “We are very pleased to be working with Alligator Bioscience. Their FIND® platform allows the development of improved versions of proteins for third parties as well as for their own internal pipeline.”
Financial terms and the therapeutic focus of the collaboration were not disclosed.
About Alligator Bioscience AB
Alligator Bioscience uses its proprietary FIND® technology to develop new and optimize existing therapeutic and diagnostic proteins.
Since 2001, Alligator Bioscience has successfully collaborated with several companies in the pharmaceutical, diagnostic and biotech industry, improving customers’ proteins and helping them to build more competitive pipelines. The company has also created an internal pipeline of therapeutic drug candidates for major clinical indications, which are at varying stages of development.
Alligator Bioscience operates from the Ideon Science Park in Lund, and has 23 employees. The company has around 150 shareholders.
For more information about Alligator Bioscience visit www.alligatorbioscience.com
About AlgoNomics NV
AlgoNomics is a Belgium based biotech company providing structural bioinformatics services to develop rationally designed therapeutics in the broad field of immunotherapy.
AlgoNomics owns a rich, proprietary platform for structure-based protein and peptide design. The technology platform contains innovative tools to unravel protein-protein and protein-peptide interactions.
AlgoNomics’ premier product is the Epibase® platform for T-cell epitope identification in different population groups, widely applied in the discovery of vaccines and therapeutic proteins.
For more information about AlgoNomics visit www.algonomics.com
Epibase® is AlgoNomics’ proprietary platform for T-cell epitope identification. This epitope discovery is applied to vaccine development in the cancer and infectious diseases field, as well as to protein epitope profiling and Immunotuning®.
The uniqueness of Epibase® resides in its capability to identify the T-cell epitopes for any collection of proteins from any biological source (viral, cancer or other), for all HLA types covering most of the human population. The approach allows to document and optimize leads such as vaccines and therapeutic proteins for any specific population.
Unlike learning-based methods, Epibase® can identify epitopes for those HLA sub-types for which little or no experimental data is available. In addition, Epibase® has the intrinsic capacity to identify epitopes sequence patterns that would not be recognized by learning-based tools.
The Epibase® platform is now able to identify helper epitopes in 77 distinct groups of HLA Class-II alleles.
- Contact Information
- Dr. Ann-Christin Malmborg Hager
- VP Business Development
- Alligator Bioscience AB
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.